Last updated: August 01, 2026

Application No. 17/818,885

HUMANIZED ANTI-C1S ANTIBODIES AND METHODS OF USE THEREOF

Non-Final OA

Filed

Aug 10, 2022

Priority

Apr 06, 2015 — provisional 62/143,636 +5 more

Examiner

HOWARD, ZACHARY C

Art Unit

1674

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Bioverativ Usa Inc.

OA Round

1 (Non-Final)

This examiner grants 64% of cases after interview

— +38.3% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 956 resolved cases, 2023–2026

Examiner Intelligence

HOWARD, ZACHARY C View full profile →

Grants 64% of resolved cases

Career Allowance Rate

611 granted / 956 resolved

+3.9% vs TC avg

Strong +38% interview lift

Without

With

+38.3%

Interview Lift

resolved cases with interview

Typical timeline

2y 10m

Avg Prosecution

61 currently pending

Career history

1007

Total Applications

across all art units

Statute-Specific Performance

§101

2.2%

-37.8% vs TC avg

§103

27.7%

-12.3% vs TC avg

§102

18.3%

-21.7% vs TC avg

§112

31.3%

-8.7% vs TC avg

Black line = Tech Center average estimate • Based on career data from 956 resolved cases

Prosecution Timeline

Aug 10, 2022

Application Filed

Dec 04, 2025

Non-Final Rejection (signed)

Jan 22, 2026

Non-Final Rejection mailed

Jul 22, 2026

Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology

18/396,301

Patent 12691181

METHODS OF TREATMENT OF CANCER WITH ANTIBODY-IL-2 ENGRAFTED PROTEINS

2y 7m to grant Granted Jul 28, 2026

17/802,499

Patent 12686860

SOLUBLE ACE2 AND FUSION PROTEINS, AND APPLICATIONS THEREOF

3y 11m to grant Granted Jul 21, 2026

18/593,002

Patent 12678483

METHODS FOR TREATING PULMONARY DISEASE WITH A LIGAND BINDING DOMAIN OF A TGF-BETA TYPE II RECEPTOR

2y 4m to grant Granted Jul 14, 2026

17/504,116

Patent 12662521

ENGINEERED OSTEOCALCINS FOR TREATING SARCOPENIA

4y 8m to grant Granted Jun 23, 2026

18/012,089

Patent 12661399

ANTI-CD2 ANTIBODIES

3y 6m to grant Granted Jun 23, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

64%

Grant Probability

99%

With Interview (+38.3%)

2y 10m (~0m remaining)

Median Time to Grant

Low

PTA Risk

Based on 956 resolved cases by this examiner. Grant probability derived from career allowance rate.